MicuRx gets positive PhII on MRX-I; Roche invests $136M in Shanghai R&D unit;

> China-focused antibiotics maker MicuRx Pharmaceuticals reported positive results for a Phase II clinical trial of candidate MRX-I, an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria. The privately held company based in California has research and development facilities in Shanghai as well. Release

> Shanghai's Zhangjiang Hi-Tech Park will see Swiss-based Roche ($RHHBY) invest $136 million to build its Roche Pharma Innovation Center as an addition to an existing Shanghai research facility started in 2004, Shanghai Daily reported. The focus for the 14,000-square-meter facility is on building ties with local research points and working alongside two other major research centers for the company in Basel and San Francisco. Report

> Changsha-based blood-sugar devicemaker Sinocare, located in China's Hunan province, will pay $273 million to buy Florida-based glucose monitoring device maker Nipro Diagnostics, a unit of Japan's Nipro Industries. Release

> China's WuXi PharmaTech ($WX) will offer preclinical medical device testing for domestic and international companies seeking China FDA product registration, Asian Scientist reported. WuXi's Laboratory Testing Division already provides similar services in the U.S. Report

> The Economic Times in India reports that Sun Pharma senior executive Sanjay Sahai has quit and has joined Alembic Pharma as head of the India formulations business. Report

> India's medical tourism receipts may hit $8 billion by 2020, according to a new CII-Grant Thornton white paper. Report